Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07832123) titled 'Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study' on Sept. 15.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of Zurich
Condition:
Glioma : Oligodendroglioma or Astrocytoma
Intervention:
Drug: Safusidenib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 2027
Target Sample Size: 20
Countries of Recruitment:
Switzerland
To know more, visit https...